Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Breast Neoplasms 65Neoplasm Metastasis 56Leukemia, Myeloid, Acute 55Multiple Myeloma 44Prostatic Neoplasms 43Melanoma 43Lung Neoplasms 39Colorectal Neoplasms 36Lymphoma 33Pancreatic Neoplasms 31Leukemia, Lymphocytic, Chronic, B-Cell 30Carcinoma, Non-Small-Cell Lung 29Myelodysplastic Syndromes 26Squamous Cell Carcinoma of Head and Neck 25Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 22Neoplasms 22Ovarian Neoplasms 21Burkitt Lymphoma 21Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Sarcoma 17Lymphoma, Mantle-Cell 17Glioma 17Uterine Cervical Neoplasms 16Rectal Neoplasms 16Leukemia, Myelomonocytic, Chronic 15Fallopian Tube Neoplasms 15Stomach Neoplasms 14

Interventions

Imatinib Mesylate 67Sunitinib 27nilotinib 14regorafenib 13ripretinib 10avapritinib 5Ipilimumab 5Dasatinib 5spartalizumab 4Laparoscopy 4CTLA-4 Antigen 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Bevacizumab 3trametinib 2tanespimycin 2ponatinib 2pembrolizumab 2masitinib 2famitinib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Stromal Tumors × Biopsy × Clear all
NCT04595747 2026-05-22

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
48 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
75 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡